J Natl Cancer Inst:乳房重建后放疗的相关并发症及病人报告结局

2018-02-14 Aries 肿瘤资讯

该前瞻性多中心研究对比了全乳切除+乳房重建术后放疗或不放疗的乳腺癌患者的并发症及病人报告结局指标。

该前瞻性多中心研究对比了全乳切除+乳房重建术后放疗或不放疗的乳腺癌患者的并发症及病人报告结局指标。结果显示自体重建更常见于放疗患者,放疗患者即刻重建率低。38.9%假体重建放疗患者、25.6%自体重建放疗患者、21.8%假体重建的非放疗患者及28.3%自体重建的非放疗患者术后2年至少出现过1次乳房相关并发症。多因素分析显示双侧手术、BMI高是术后并发症的预测因素,并且与是否放疗及重建类型相关。对于放疗患者,相比于假体重建者,自体重建者术后两年的并发症率更低。对于非放疗患者,自体重建及假体重建者的并发症率无统计学差异。自体重建者的病人满意度较假体重建者的好。因此,对于全乳切除术后放疗患者,自体重建并发症少,满意度更高。

原始出处:

Reshma Jagsi,et al.Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.J Natl Cancer Inst.Volume 110, Issue 2, 1 February 2018, djx148.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757945, encodeId=5dc51e579459f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Feb 24 02:50:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882856, encodeId=e510188285687, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 02 20:50:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977546, encodeId=10ea19e7546a8, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jan 03 06:50:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800313, encodeId=afbc1800313eb, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Mar 19 01:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950222, encodeId=fdab195022202, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Sep 25 10:50:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287920, encodeId=3ed828e920b4, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Wed Feb 14 15:13:43 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-24 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757945, encodeId=5dc51e579459f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Feb 24 02:50:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882856, encodeId=e510188285687, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 02 20:50:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977546, encodeId=10ea19e7546a8, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jan 03 06:50:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800313, encodeId=afbc1800313eb, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Mar 19 01:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950222, encodeId=fdab195022202, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Sep 25 10:50:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287920, encodeId=3ed828e920b4, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Wed Feb 14 15:13:43 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-03-02 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757945, encodeId=5dc51e579459f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Feb 24 02:50:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882856, encodeId=e510188285687, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 02 20:50:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977546, encodeId=10ea19e7546a8, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jan 03 06:50:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800313, encodeId=afbc1800313eb, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Mar 19 01:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950222, encodeId=fdab195022202, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Sep 25 10:50:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287920, encodeId=3ed828e920b4, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Wed Feb 14 15:13:43 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2019-01-03 drj2003
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757945, encodeId=5dc51e579459f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Feb 24 02:50:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882856, encodeId=e510188285687, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 02 20:50:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977546, encodeId=10ea19e7546a8, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jan 03 06:50:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800313, encodeId=afbc1800313eb, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Mar 19 01:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950222, encodeId=fdab195022202, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Sep 25 10:50:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287920, encodeId=3ed828e920b4, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Wed Feb 14 15:13:43 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757945, encodeId=5dc51e579459f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Feb 24 02:50:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882856, encodeId=e510188285687, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 02 20:50:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977546, encodeId=10ea19e7546a8, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jan 03 06:50:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800313, encodeId=afbc1800313eb, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Mar 19 01:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950222, encodeId=fdab195022202, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Sep 25 10:50:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287920, encodeId=3ed828e920b4, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Wed Feb 14 15:13:43 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-09-25 qidongfanjian
  6. [GetPortalCommentsPageByObjectIdResponse(id=1757945, encodeId=5dc51e579459f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Feb 24 02:50:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882856, encodeId=e510188285687, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 02 20:50:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977546, encodeId=10ea19e7546a8, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Jan 03 06:50:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800313, encodeId=afbc1800313eb, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Mar 19 01:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950222, encodeId=fdab195022202, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Sep 25 10:50:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287920, encodeId=3ed828e920b4, content=^_^^_^^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Wed Feb 14 15:13:43 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-14 wqkm

    ^_^^_^^_^

    0

相关资讯

《中国晚期乳腺癌维持治疗专家共识》(2018)要点

乳腺癌是女性最常见的恶性肿瘤之一。我国女性乳腺癌发病率逐年升高,每年新发患者约27万例,其中3%~8%的乳腺癌患者初诊时即为转移性。即使接受了手术及规范治疗的早期患者,仍有30%~40%会复发转移。晚期乳腺癌目前虽难以治愈,但可通过研发新型治疗药物,优化治疗模式等方法来缓解患者的临床症状,改善患者的生活质量,进一步延长患者的生存期。维持治疗的理念早在白血病治疗中被提出,而后在非小细胞肺癌和肠癌等实

J Clin Oncol:拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌

该研究旨在评估内分泌治疗和一线曲妥珠单抗+化疗经治的HR+HER2+绝经后乳腺癌患者,使用抗HER2双靶治疗联合AI的疗效和安全性。

Oncogenesis:伊马替尼或可靶向治疗某些雌激素受体阳性乳腺小叶浸润癌

该研究使用新的雌激素受体阳性ILC模型(BCK4)和基因表达阵列发现,BCK4细胞系和异种移植肿瘤大约200个重叠基因受到体外雌激素调节,根据通路分析显示,c-Kit通路可能成为减少雌激素诱导乳腺癌细胞增殖的靶点。

NPJ Breast Cancer:卵巢切除术显著影响绝经前雌激素受体阳性乳腺癌基因表达

该研究分析了卵巢切除术对56例绝经前雌激素受体阳性乳腺癌女性乳房切除术前两周内分泌和全基因组转录的影响。

Eur J Cancer:筛查间期检出 HER2 阳性早期乳腺癌患者预后较差,应积极治疗

该研究对病理分期T1aN0M0乳腺癌的874例50~69岁女性进行分析,并排除未接受筛查、HER2状态未知、接受曲妥珠单抗辅助治疗的患者。

Eur J Cancer:根据HR+HER2+乳腺癌患者年龄选择更佳内分泌辅助治疗方案

该研究通过荷兰癌症登记数据库找出2005~2007年所有被诊断为任何肿瘤大小和淋巴结分期、未转移、ER伴HER2阳性乳腺癌并接受过内分泌治疗的女性共1155例。